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7Commentary on T1-Weighted Hypersignal in
the Deep Cerebellar Nuclei After Repeated
Administrations of Gadolinium-Based Contrast
Agents in Healthy Rats
Difference Between Linear and Macrocyclic Agents
Val M. Runge, MD
I n this landmark article by Robert et al, an animal model is presented for the T1 signal hyperintensity inthe deep cerebellar nuclei, including specifically the dentate nucleus, after intravenous administration
of the linear gadolinium-based contrast agent gadodiamide (Omniscan) in normal renal function.1 This
change was further demonstrated to correlate with higher gadolinium concentration in the brain, as de-
termined by inductively coupled plasma mass spectrometry. No abnormality was noted after administra-
tion of a macrocyclic agent, gadoterate meglumine (Dotarem). The study provides a scientific basis for
previous clinical observations, together with a platform for rigorous further investigation. In-depth study,
using this model or similar models, of all of the approved gadolinium-based contrast agents (GBCAs)
is warranted.
Including the current research, there are 8 published articles to date examining this critical topic.
The first two appeared in 2014, demonstrating in patients with normal renal function the progressive in-
crease of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance (MR) images
with increasing cumulative dose of gadodiamide.2,3 Subsequent clinical studies by the same 2 groups ap-
peared in 2015, together with an additional publication from Germany, confirming the finding to be as-
sociated with prior gadodiamide administration, identifying that this also occurs with the linear GBCA
gadopentetate dimeglumine (Magnevist) and demonstrating the lack of any abnormality in patients who
had received themacrocyclic agent gadoteratemeglumine.4–6 Additional studies on tissue from deceased
patients in 2015 identified gadolinium deposition in neuronal tissue (in patients with prior administration
of gadodiamide or gadopentetate dimeglumine) and in the larger study in a dose-dependent relationship
correlating with signal intensity changes on precontrast T1-weighted scans, without detectable levels in
controls.7,8 Of critical importance is that this phenomenon is observed in the setting of relatively normal
renal function.
This topic and its evolution bring to mind that of nephrogenic systemic fibrosis (NSF). The initial
article by Thomas Grobner9 in 2006 alerted the community to the correlation between NSF and adminis-
tration of gadodiamide and was followed in 2007 by an article suggesting in vivo dechelation as the root
cause.10 By 2008, it had been established that “the risk of NSF is unexpectedly and unacceptably high
(18%) in patients with stage 5 chronic kidney disease (CKD5) exposed to gadodiamide”.11 In 2008 and
2009, research emerged using an animal model, confirming the correlation between disease development
and chelate stability, with gadolinium deposition noted in tissues.12–14 These and other studies led to the
current clinical guidelines, as reflected by the ninth version of the Contrast Media Guidelines from
the Contrast Media Safety Committee of the European Society of Urogenital Radiology. In summary,
gadodiamide (Omniscan), gadopentetate dimeglumine (Magnevist), and gadoversetamide (Optimark)
are contraindicated in patients with CKD stages 4 and 5, acute renal failure, pregnant women, and neo-
nates. Caution is suggested in patients with CKD stage 3 and in children younger than 1 year. Estimated
glomerular filtration rate measurement and clinical assessment of patients before contrast administration
are mandatory. These 3 agents are considered to have the highest risk of NSF (and the recommendations
being specific to this group). In distinction, the 3 macrocyclic agents—gadobutrol (Gadovist, Gadavist),
gadoterate meglumine (Dotarem), and gadoteridol (Prohance)—are considered to have the lowest risk
of NSF.
Stability in vivo of the gadolinium chelates is fundamental to the safety basis of this class of con-
trast media. This has been emphasized throughout the evolution of the field,15 indeed since the very first
public presentation of results using a paramagnetic metal chelate.16 High thermodynamic and kineticMay 7, 2015; and accepted for publication, after revision, May 7, 2015.
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Commentary Investigative Radiology • Volume 50, Number 8, August 2015stability was identified in the literature as a critical feature as early as
1983,17 with the importance of in vivo stability reiterated in 1984 at
the American Society of Neuroradiology in presentation of the first re-
search demonstrating potential clinical utility.18 By the early 1990s, the
higher in vivo stability of the macrocyclic agents, with transmetallation
occurring only very slowly, was well known with approval of Dotarem
in 1989 in France and Prohance in 1992 in the United States.19 This
safety basis has been re-emphasized in many review articles, two of
which are cited.20,21 Statements of note from 2000 should be reiter-
ated20: “The safety of the gadolinium chelates is largely based on their
stability in vivo. The chelates were designed to bind the gadolinium ion
extremely tightly, thus ensuring nearly complete renal excretion of the
intact chelate” and “A major safety concern in the development of this
class of agents is the possible release of free gadolinium in vivo.”
The field of medicine has radically changed in the past 30 years.
Our clinical colleagues heavily rely on imaging, and specifically MR
and computed tomography, for disease diagnosis, management, and
treatment monitoring. Yet, my greatest concern in 1982, at the begin-
ning of my career, was that the area I had picked as my focus, MR im-
aging, had already peaked in its development. Little did I know that I
would be the individual to first suggest publicly the use of paramagnetic
metal ion chelates as intravenous contrast media, with today approxi-
mately 30 million doses given each year and more than 300 million ad-
ministrations since clinical approval of the first agent, Magnevist, in
1987. In the meantime, we have seen consolidation of the pharmaceuti-
cal industry, development of group purchasing organizations, and an in-
tense focus on profitability and blockbuster drugs, all of which could be
considered to be negative developments with regard towhat should be a
physician’s focus, the safety of any administered agent. Adding to this
is another huge negative factor, specifically that the cost of developing
an agent for diagnostic imaging has exploded to more than 200 million
dollars, representing a significant brake on new development.22 Im-
provements in the approval process (streamlining and lowering costs)
and reinvestment by the pharmaceutical industry to develop new agents
should be strongly encouraged. Chemistry is far advanced today in
comparison to 30 years ago when both the linear and macrocyclic gad-
olinium chelates were conceptualized, making possible substantial im-
provements in design, stability (safety), and relaxivity (efficacy).
The gadolinium chelates (the GBCAs) are critical to disease di-
agnosis byMR, indeed to clinical medicineworldwide, and have proven
to be overall a very safe class of contrast media. However, the article
of reference in this issue of Investigative Radiology should serve as a
call for further research as well as re-evaluation by the pharmaceutical
regulatory agencies worldwide. All of the currently approved GBCAs
should be evaluated by the methods used in the article by Robert et al,
or by a similar approach. This could lead, and if so appropriately, to the
reassessment of the approval status of the least stable agents. As physi-
cians, let us remember, above all, to do no harm.REFERENCES
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